Abbott Laboratories
Abbott Laboratories
Your view on ABT
Overview
What the company does, where it operates, and who runs it.
About Abbott Laboratories
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Robert B. Ford
- Headquarters
- 100 Abbott Park Road, North Chicago, IL, US
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Robert B. Ford
- Headquarters
- 100 Abbott Park Road, North Chicago, IL, US
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.
The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories.
The Nutritional Products segment provides pediatric and adult nutritional products.
The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders.
Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
Fair value for Abbott Laboratories from FRC's valuation model, read against the market price. ABT last traded at $109.35, 40.7× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Abbott Laboratories. Starting points for Abbott Laboratories: P/E 40.7, EPS $2.71, beta 0.54 — an Medical - Devices name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Abbott Laboratories. Abbott Laboratories paid $2.52 per share over the last year — a 2.3% yield at the current $109.35 price. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Abbott Laboratories. Trailing twelve-month EPS for Abbott Laboratories stands at $2.71. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
1-Year Price Target
Low
$112.00
Median
$120.00
High
$130.00
Average target · 6 new targets in the last month, average $121.17
Analyst Ratings
- Strong Buy0
- Buy33
- Hold10
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $1.64 | $1.23 | $5.52 | $5.93 |
| Low estimate | $1.63 | $1.21 | $5.50 | $5.90 |
| High estimate | $1.65 | $1.25 | $5.53 | $6.06 |
| No. of analysts | 15 | 11 | 17 | 18 |
| Year-ago EPS | $1.02 | $0.62 | $3.72 | — |
| Growth | +60.6% | +98.4% | +48.3% | — |
Revenue Estimate
| Revenue | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $13.21B | $12.57B | $49.98B | $53.64B |
| Low estimate | $12.78B | $12.36B | $49.25B | $52.08B |
| High estimate | $13.31B | $12.75B | $50.15B | $54.33B |
| No. of analysts | 15 | 11 | 20 | 21 |
| Year-ago revenue | $11.46B | $11.16B | $44.33B | — |
| Growth | +15.3% | +12.6% | +12.8% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga, Pulse 2.0, Investing; as of Nov 12, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Abbott Laboratories. Abbott Laboratories has reported as a listed company since 1980. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Abbott Laboratories valued side by side against its closest peers. Abbott Laboratories is measured against Medical - Devices peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
Which funds and firms own the stock.
Which institutions hold Abbott Laboratories, and how their positions are changing. At a $189.39B market value, institutional positions materially move Abbott Laboratories's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by Abbott Laboratories executives and directors. Shares of Abbott Laboratories have traded between $110.86 and $141.23 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Abbott Laboratories. Abbott Laboratories is a $189.39B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Abbott Laboratories. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Abbott Laboratories. Coverage tracks Abbott Laboratories within Medical - Devices (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Abbott Laboratories.